AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00712686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Capsule, Oral, 10-20 mg, once daily, 140 weeks
Study NCT02263196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol and povidone iodine
Description: using from Alcohol and povidone iodine for prevention of inflammation
Study NCT02263196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of alcohol and betadin
Description: using from combination Alcohol and povidone iodine for prevention of inflammation
Study NCT03645941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Group
Description: The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
Study NCT03052634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 1.5 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study NCT03052634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.0 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study NCT03052634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.5 mg/kg (HER2 Positive)
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study NCT02063360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT03052634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
Description: 45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study NCT03424616 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
Study NCT03424616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
Study NCT03564210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen time permitted
Description: Cohort will not be directed to abstain from screen time
Study NCT03564210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen Time Abstain
Description: Cohort will be directed to abstain from screen time
Study NCT02063360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir (DRV)
Study NCT02063360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir (RTV)
Study NCT02063360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: Etravirine (ETR)
Study NCT00569478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Nursing consultations and physical training
Study NCT01057342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
Study NCT01057342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
Study NCT01057342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadimezan
Description: 1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
Study NCT03789344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
Study NCT03789344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
Study NCT03789344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blank control
Description: Blank control subjects would be observed only during this investigation.
Study NCT04226001 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Quality of life questionnaire
Study NCT02118402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified maize porridge
Description: Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
Study NCT03375203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered once daily based upon dosing group.
Study NCT00491751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 40 or 80 mg/day
Study NCT00491751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: ascorbic acid 500 mg/day
Study NCT00491751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT03938558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS-Dance
Description: The experimental group will perform 10 weeks of dance training
Study NCT03938558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MS-Art
Description: The other group will contribute to the production in various ways (e.g. word art, photography, painting, ...)
Study NCT03375203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 5 mg
Description: JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
Study NCT03375203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 10 mg
Description: JNJ-42847922 will be administered as 10 mg oral capsule once daily.
Study NCT03375203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 20 mg
Description: JNJ-42847922 will be administered as 20 mg oral capsule once daily.
Study NCT03375203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
Study NCT03653910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq
Description: Airtraq is a kind of videolaryngoscope for intubation
Study NCT03653910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Macintosh is a traditional laryngoscope for intubation
Study NCT02155543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation A
Description: One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
Study NCT02155543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation B
Description: One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
Study NCT02155543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Formulation C
Description: One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
Study NCT02155543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-223575 Vehicle
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
Study NCT02155543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-223575 Vehicle
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
Study NCT02181504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
Study NCT02181504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
Study NCT02181504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at weeks 12 and 16.
Study NCT01884337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02266134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
Study NCT02266134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
Study NCT03621501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
Study NCT03621501 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
Study NCT00182468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for intimate partner violence
Description: Women are screened for intimate partner violence prior to seeing a health care provider.
Study NCT00802880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT00823186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyxol(Paclitaxel)
Description: Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine
Study NCT00983242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
Study NCT00983242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCl ER
Description: One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
Study NCT00983242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
Study NCT04374149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange
Description: TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
Study NCT04374149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
Study NCT02014545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucanthone
Description: The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
Study NCT02014545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only standard treatment of whole brain radiation therapy is done.
Study NCT02204111 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
Study NCT04008667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupoint application
Description: Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
Study NCT04008667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fake acupoint application
Description: Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
Study NCT03518463 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery after surgery (ERAS)
Description: The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Study NCT03518463 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Study NCT03194204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Tablets
Description: MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
Study NCT04120350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Study NCT04120350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Study NCT04120350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years.
Study NCT02736474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
Study NCT02736474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Naltrexone
Description: Placebo Naltrexone created and masked by the pharmacy to be used as a control.
Study NCT04259437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein, Energy Dense Nutritional Supplement
Description: Ready to drink oral supplement
Study NCT02736474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
Study NCT02736474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bupropion
Description: Placebo Bupropion created and masked by the pharmacy to be used as a control.
Study NCT01369069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV insulin to maintain target glucose concentration of 80-130 mg/dL
Description: Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
Study NCT01369069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Description: Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
Study NCT04280081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT00821756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPAC (Outreach, Problem solving, Adherence, Continuity)
Description: Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
Study NCT02483351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal Red Blood Cell Transfusion Strategy
Description: RBC Transfusion strategy with hemoglobin trigger of 100g/L
Study NCT03941964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
Study NCT03941964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
Study NCT03941964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.